[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Pages 85894-85895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-27114]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

[[Page 85895]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Theodoric Mattes at 240-627-3827, or 
<a href="/cdn-cgi/l/email-protection#97e3fff2f8f3f8e5fef4b9faf6e3e3f2e4d7f9feffb9f0f8e1"><span class="__cf_email__" data-cfemail="daaeb2bfb5beb5a8b3b9f4b7bbaeaebfa99ab4b3b2f4bdb5ac">[email protected]</span></a>. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen 
In Humans And Pigs

    Description of Technology: The pork tapeworm, Taenia solium, is 
endemic in most of Asia, Latin America, and Sub-Saharan Africa. The 
risk of infection is increased in regions where pigs are raised in 
closed proximity to humans, with migration from endemic regions being 
directly proportional to the prevalence of infection in high-income 
countries. Human infection by T. solium occurs following oral ingestion 
of eggs passed in human feces from an infected carrier. The larvae can 
travel anywhere in the human body. Neurocysticercosis (NCC) occurs when 
the larvae traverse the blood-brain barrier and penetrate the central 
nervous system. Diagnosis of NCC is typically made through radiological 
imaging studies (such as computed tomography or magnetic resonance 
imaging) to visualize the morphology, stage, and location of the cysts.
    Investigators at NIAID have developed the recombinant IgG 
monoclonal antibody known as TsG10, which can target T. solium 
circulating antigens. An expression vector to produce TsG10 is 
available for expression in mammalian cell lines. The resulting 
construct allows for a scalable, repeatable, and broadly accessible 
production of monoclonal antibodies for both human and veterinary use. 
The TsG10 monoclonal antibodies are adaptable for plate-based 
diagnostic assays like ELISAs, to support a diagnosis of NCC.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

<bullet> Plate-based diagnostic immunoassays, both human and 
veterinary, for the detection of T. solium circulating antigen
<bullet> Production of TsG10 recombinant monoclonal antibodies

    Competitive Advantages:

<bullet> Detection of active T. solium infection
<bullet> Scalable and repeatable production of a monoclonal antibody 
targeting T. solium
<bullet> Materials available for development or licensing

    Development Stage:
<bullet> Research Material

    Inventors: Drs. Thomas B. Nutman, Elise O'Connell, Theodore E. 
Nash, Siddhartha Mahanty, Hector Garcia, Adriana Paredes, all of NIAID
    Intellectual Property: HHS Reference No. E-043-2022-0
    Licensing Contact: To license this technology, please contact 
Theodoric Mattes at 240-627-3827, or <a href="/cdn-cgi/l/email-protection#96e2fef3f9f2f9e4fff5b8fbf7e2e2f3e5d6f8fffeb8f1f9e0"><span class="__cf_email__" data-cfemail="deaab6bbb1bab1acb7bdf0b3bfaaaabbad9eb0b7b6f0b9b1a8">[email protected]</span></a>., and 
reference E-043-2022-0.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this technology. For collaboration 
opportunities, please contact Theodoric Mattes at 240-627-3827, or 
<a href="/cdn-cgi/l/email-protection#95e1fdf0faf1fae7fcf6bbf8f4e1e1f0e6d5fbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="a5d1cdc0cac1cad7ccc68bc8c4d1d1c0d6e5cbcccd8bc2cad3">[email protected]</span></a>.

     Dated: December 5, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-27114 Filed 12-8-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>